IMNM Immunome, Inc.
Immunome, Inc. (IMNM) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.61 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.8% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Immunome, Inc.
Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.
Sector
Healthcare
Industry
Biotechnology